Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer gets full rights to Vitrakvi, LOXO-195 from Lilly’s Loxo Oncology
Bayer has obtained the full rights to global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from the US-based Loxo Oncology.
Research & Development
-
18 Feb 2019
-
15 Feb 2019
SK, Arvelle sign $530m deal for antiepileptic drug cenobamate
SK Biopharmaceuticals has entered into a $530m deal with the Arvelle Therapeutics for investigational antiepileptic drug cenobamate.
-
15 Feb 2019
Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML
Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, has announced a $42m Series A financing round led by 5AM Ventures and RA Capital Management.
-
12 Feb 2019
AbbVie, Teneobio sign deal to develop new treatment for multiple myeloma
AbbVie, Teneobio, and its affiliate TeneoOne have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
-
11 Feb 2019
Samsung Bioepis, C-Bridge Capital to develop and commercialize next-generation biosimilars in China
Samsung Bioepis has announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.
-
11 Feb 2019
Evotec, Galapagos enter into collaboration in fibrosis field
Evotec and Galapagos have announced a global collaboration focused on a novel target for fibrosis and other indications.
-
08 Feb 2019
Ligand announces OmniAb partnership with Genagon Therapeutics
Ligand Pharmaceuticals has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.
-
08 Feb 2019
TamRx launches to develop pipeline of immuno-oncology products for treatment of cancers
BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, announced the formation of a new biotech start-up, TamRx.
-
07 Feb 2019
Frazier Healthcare Partners launches Recida Therapeutics to develop therapeutics for serious antibiotic-resistant infections
Frazier Healthcare Partners has launched Recida Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections.
-
06 Feb 2019
GSK, Merck enter into €3.7bn deal for novel cancer treatment
GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal.